Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Not sure myself. Company has been very quiet. Will give them til the end of year. The last Q was disappointing so its time to put up or shut up.
GLTA & JMO
Junk,
I'm not getting that, It's time to average down feeling this go round. Stock of late seems stale and moribund. Any good news coming?
OK. Mix-ups happen. Could be worse. At least the nude selfie you were going to sext to your GF didn't go to your mom! Seriously, PM me offline and maybe I can advise you some more.
Yup, wrong board, has nothing to do with BJCT. We have the IP in place and are looking to contact someone at BJCT. Sorry for any false alarms here.
Are you posting on the correct board? What does this have to do with SMME? Twentieth time? I think I have only responded twice.
My comment on IP protection is that YOU should have IP protection for the idea you are wanting to bring to BJCT (or anyone else) so you don't get screwed. Trying to look out for your best interests.
Well, this goes back to my point. What don't you get.... you said no one is going to talk to someone off the street without IP protection. Sarbanes Oxley (SEC Public Company reporting ) REQUIRES all IP assets, etc...even a license, to be disclosed. So again, for the twentieth time, where is SMME's biometric patent for use of that technology on its card.....its certainly NOT and "obvious" use that would allow it to except it from registration and exemption. Ahhh....you, or anyone else can prove THAT, point to anything in this companies filings......but I will absolutely say, if the use of that technology infringes in any way, another company's patent, without an express and disclosed license to use it, IMHO there will be a cease and desist. Its always better to get your house in order before inviting guests to pay for admission.
And for the poster who criticized my spelling and grammar, I do this between surgeries....., so I am not always thinking about grammar and spelling....and thats the least of this companies problems. Typical liberal...attack the messenger.
Too bad. Is there somewhere else you can go? Also, most companies aren't going to listen to someone off the street unless they have IP protection and a prototype at the minimum. Also, if it can get thru the FDA 401K process and have it linked to CPT codes for billing.
I still can't reach anyone.......
Smaller loss, but less revenue. Reminds me of a Dilbert cartoon where they are discussing similar losses with the pointy hair boss and the solution to cutting losses is to stop selling. I was hoping they would have increased sales via their foreign partnerships.
BIOJECT REPORTS UNAUDITED SECOND QUARTER 2015 FINANCIAL RESULTS
Tigard, OR – August 14, 2015 – Bioject Medical Technologies Inc. (OTC Pink: BJCT), a developer and
manufacturer of needle-free injection therapy systems, today reported unaudited financial results for the
second quarter ended June 30, 2015. The financial results are unaudited and actual results may vary.
Bioject reported revenues of $215,000 for the quarter ended June 30, 2015, compared to revenues of
$513,000 in the comparable 2014 period. Operating expense was $392,000 for the second quarter of 2015,
compared to $788,000 in the second quarter 2014. The Company reported an operating loss of $177,000 in
the second quarter of 2015, compared to an operating loss of $275,000 in the second quarter of 2014. Net
loss allocable to common shareholders for the second quarter of 2015 was $276,000, compared to $331,000
in the comparable 2014 period.
Basic and diluted net loss per share allocable to common shareholders for the quarter ended June 30, 2015
was $0.01 per share on 39.1 million weighted average shares outstanding compared to a basic and diluted
net loss of $0.01 per share on 32.4 million weighted average shares outstanding for the same period in 2014.
For the six months ended June 30, 2015, Bioject reported revenues of $529,000, compared to revenues of
$855,000 in the comparable period of 2014. Operating expense was $959,000 for the six-month period of
2015, compared to $1.4 million for the comparable period of 2014. The Company reported an operating loss
of $430,000 for the six-month period of 2015, compared to $534,000 in the comparable period of 2014. Net
loss allocable to common shareholders was $603,000, or $0.02 per basic and diluted share on 39.0 million
weighted average shares outstanding in the six-month period ended June 30, 2015 compared to $647,000, or
$0.03 per basic and diluted share on 25.7 million weighted average shares outstanding in the comparable
period of 2014.
Bioject Medical Technologies Inc., based in Tigard, Oregon, USA, is a developer and manufacturer of
needle-free injection therapy systems (NFITS). NFITS works by forcing medication at high speed through a
tiny orifice held against the skin. This creates a fine stream of high-pressure fluid penetrating the skin and
depositing medication in the tissue beneath. Bioject is focused on developing mutually beneficial
agreements with leading pharmaceutical, biotechnology, and veterinary companies, as well as research,
global health and government organizations.
If you have access to PM, check your mailbox.
I have been trying to reach someone at Bioject to discuss a game-changing technology to improve the companies product. I have emailed and called, and got nothing. The technology I am interested in introducing to this company is already in the market and will set this companies product light years ahead of PharmaJet, Injex, Zogenix, etc...... So whats going on?
Nice to see some activity here.
Today appears to be accumulation, but yesterday saw signs of a seller at .05
Would be nice to get some filings
A lot of shares sold today. Significant?
Am still accumulating.
Probably time to average down
Just looks like someone is selling some of their position.
If it gets any lower I'll be scooping a bunch up.
GLTA & JMO
Any idea what's going on with the PPS?
I expect the company to B/E in Q3 of this year.
It has been tough sledding for all NFITS ever since the FDA caved in to lobbyists.
We will have our day and the world will be better for it.
GLTA & JMO
Hi! I remember looking at this once a long time ago...
looks like its been a bumpy ride...
What are the odds of a turn around?
Don't think so.. Not yet anyways. They are slowly moving towards B/E and after they attain positive cash flow they can ramp up visibility.
GLTA & JMO
Does this company ever present to Investor Conferences
BIOJECT REPORTS UNAUDITED FIRST QUARTER 2015 FINANCIAL RESULTS
Tigard, OR – May 15, 2015 – Bioject Medical Technologies Inc. (OTC Pink: BJCT), an innovative developer and manufacturer of needle-free injection therapy systems, today reported unaudited financial results for the first quarter ended March 31, 2015. The financial results are unaudited and actual results may vary.
Bioject Medical Technologies Inc., based in Tigard, Oregon, USA, is an innovative developer and manufacturer of needle-free injection therapy systems (NFITS). NFITS works by forcing medication at high speed through a tiny orifice held against the skin. This creates a fine stream of high-pressure fluid penetrating the skin and depositing medication in the tissue beneath. Bioject is focused on developing mutually beneficial agreements with leading pharmaceutical, biotechnology, and veterinary companies, as well as research, global health and government organizations.
Hi Ted, Im here. Nothing changed for me. I have most of the others on ignore; easier than having to set them straight. Seems to be a lot of misinformation and twisting of facts so Im going to refrain from validating their comments by replying. You know what they say about arguing with an idiot.
These unmoderated YMB are cesspools for shorts and novice investors.
BJCT will be fine.. if you can afford to hold I think we should be ok towards end of this year.
GLTA & JMO
Once they get caught up on filings and achieve b/e with cash flow the market will put some eyes on BJCT. They are slowly digging themselves out of a major ditch that the FDA put them and all NFIT companies in.
Nice to see revenues improving overall and distribution/adoption broadening.
GLTA & JMO
BIOJECT REPORTS UNAUDITED YEAR-END AND FOURTH QUARTER 2014 FINANCIAL RESULTS
Tigard, OR – March 25, 2015 – Bioject Medical Technologies Inc. (OTC Pink: BJCT), a developer and manufacturer of needle-free injection therapy systems, today reported unaudited financial results for the year and quarter ended December 31, 2014. The financial results are unaudited and actual results may vary.
12 Months Ended December 31, 2014
- Revenue for the twelve months ended December 31, 2014 was $1.8 million, compared to $1.5 million in 2013;
- Operating expense for 2014 was $2.7 million, compared to $2.5 million in 2013;
- Operating loss for 2014 was $907,000, compared, to $969,000 in 2013; and
- Net loss allocable to common shareholders for 2014 was $1.1 million on 32.4 million shares outstanding, or $(0.04) per diluted share, compared to $1.1 million on 18.9 million shares outstanding, or $(0.06) per diluted share, in 2013.
Three Months Ended December 31, 2014
- Revenue for the quarter ended December 31, 2014 was $513,000 compared to $384,000 in the quarter ended December 31, 2013;
- Operating expense for the 2014 quarter was $763,000, compared to $116,000 in the 2013 quarter. The 2013 operating expense of $116,000 included the reversal of $497,000 of expense related to unclaimed inventory credits;
- Operating loss for the 2014 quarter was $250,000, compared to an operating income of $268,000, in the 2013 quarter; and
- Net loss allocable to common shareholders for the 2014 quarter was $305,000, or $(0.01) per diluted share, compared to a net income of $215,000, or $0.01 per diluted share, in the 2013 quarter.
$513,000 in revs with a 2m market cap. Their device has a demand in the markets. I think it's a good buy here
Hopefully BJCT has been able to rectify that impediment.
I have a feeling they did.
GLTA & JMO
Thanks. I was pleasantly surprised to see them wrap up a market like Mexico.
I believe they are already queued for other companies serviced by the same distributor.
Waiting on the next Q to see if I should buy more now or later. :)
GLTA & JMO
Nice finds on the Mexican and Moroccan news. Just saw the Mex news elsewhere.
I was happy to see the UTEP article. I hope the work eventually gets directed towards the US market. At a cattle feeding conference last May, I asked a Merck scientist -- after he gave a talk on stress reduction-- if he was aware of any needle free injection systems on the horizon. He said he was not, that as far as he knew hide thickness was still the impediment.
Thanks. Nice support statement for the Needle Free tech which Bioject has.
Its also encouraging to see BJCT leverage their existing relationships and provide a compelling alternative solution to this kind of problem for livestock.
A paragraph taken from a WHO article on Rift Valley Fever:
Animal immunization must be implemented prior to an outbreak if an epizootic is to be prevented. Once an outbreak has occurred animal vaccination should NOT be implemented because there is a high risk of intensifying the outbreak.During mass animal vaccination campaigns, animal health workers may, inadvertently, transmit the virus through the use of multi-dose vials and the re-use of needles and syringes. If some of the animals in the herd are already infected and viraemic (although not yet displaying obvious signs of illness), the virus will be transmitted among the herd, and the outbreak will be amplified.
This should serve as a reminder that the reach of Bioject goes beyond human applications and they have had strong relationships with livestock and veterinarian distribution in the past.
GO BJCT. I know my dog would much rather have NFIS than a scary needle.
GLTA & JMO
The growth of the foothold continues.. Mexico is a huge market potentially. And it opens the door to neighbouring countries.
GLTA & JMO
Bioject To Provide Needle-Free Livestock Vaccine Delivery System for University of Texas and MCI Sante-Animale
PRESS RELEASE
El Paso, Texas. February, 21 2015. University of Texas at El Paso signs a development agreement with MCI Sante-Animale, Mohammedia, Morocco to help develop, manufacture, license and distribute a veterinary vaccine in Africa and the Middle East that prevents Rift Valley fever disease in livestock.
The University of Texas at El Paso (UTEP) today announced that it has signed a joint development agreement with MCI Sante-Animale Biopharmaceutical Company (MCI) in Morocco to manufacture and sell a Rift Valley fever (RVF) vaccine in Africa and the Middle East. UTEP is the lead developer and is working under a major cooperative agreement with the U.S. Agency for International Development (USAID) to continue the testing of a recombinant RVF MP-12 based animal vaccine. The project is part of the Feed the Future Innovation Lab for Rift Valley Fever Control in Agriculture with a goal of protecting livestock against the disease. This will help to increase global food security, which is a priority of USAID under Feed the Future, the U.S. Government’s global hunger and food security initiative.
MCI-Sante-Animale is a major veterinary products developer and manufacturer, fully certified and working under Good Manufacturing Practices. It is based in Morocco and dedicated to providing solutions to nutrition and infectious disease problems affecting companion animals and livestock. The company has developed several viral based vaccines for livestock and other animal diseases, and has started a program to address the problem of RVF. MCI will adapt the vaccine into its commercial live attenuated virus vaccine manufacturing process. It will also obtain in-country licenses across Africa and the Middle East where RVF has had a devastating impact on the health of domestic and feral animals as well as humans, and is a costly problem for agriculture. UTEP, along with its technical partners in the program, The University of Texas Medical Branch (UTMB) in Galveston, TX and The Sokoine UnIversity of Agriculture (SUA), School of Veterinary Medicine, Morogoro, Tanzania will provide technical support to establish the safety and efficacy parameters of the vaccine.
The RVF MP-12 vaccine was originally developed by Dr. C.J. Peters and colleagues at the U.S. Army Medical Research Institute for Infectious Disease at Ft. Detrick, Maryland. The vaccine used in this project is a live, attenuated vaccine derived from the MP-12 vaccine but modified to distinguish naturally infected animals from vaccinated animals by deleting a non-essential nonstructural gene from the RVF viral genome.
Finally, Bioject Inc. in Tigard, Oregon will provide a needle-free vaccine delivery system to simplify the vaccination process, allowing for wider use of the vaccine in Africa.
The establishment of the partnership leading to the availability of this improved vaccine will make possible the prospect of RVF regional vaccine banks or strategic reserves, which could improve the control of this devastating disease. The Feed the Future Innovation Lab for Rift Valley Fever Control in Agriculture builds upon previous federally funded research directly applicable to both the animal and human form of RVF disease, and reflects the growing recognition of UTEP’s and collaborating institutions’ capability and interest in contributing to the improvement of both food security and global health.
For further information please contact Dr. George Bettinger, The University of Texas El Paso (gebettinger@utep.edu) or Dr. Baptiste Dungu, MCI-Sante Animale, Mohammedia, Morocco (B.DUNGU@mci-santeanimale.com).
USAID is the lead US Government agency that works to end extreme global poverty and enable resilient, democratic societies to realize their potential.
Feed the Future (www.feedthefuture.gov) is the U.S. Government’s global hunger and food security initiative. With a focus on smallholder farmers, particularly women, Feed the Future supports partner countries in developing their agriculture sectors to spur economic growth and trade that increase incomes and reduce hunger, poverty and undernutrition.
BIOJECT ENTERS INTO A DISTRIBUTION AGREEMENT WITH BIOMEDICS SA FOR ITS
FULL LINE OF NEEDLE FREE INJECTION TECHNOLOGY IN MEXICO
Agreement increases the availability of Bioject products in a key market in the America’s and is another step in the Company’s global marketing strategy.
Tigard, OR –March 3, 2015 – Bioject Medical Technologies Inc. (OTC Pink: BJCT), a leading developer and manufacturer of needle-free injection technology, today announced that it has entered into a
distribution agreement with Biomedics , a leading medical supplies company based in Mexico City. Under the terms of this agreement, Biomedics will be the exclusive distributor of Bioject’s commercial needle-free injection products in Mexico and will now service Bioject’s current customers in Mexico. Product registration is already underway for those devices not yet approved for sale.
Stated Tony Chow, Bioject’s President and CEO, “Abraham Renner and his team are a great addition to our efforts to provide access to our technology around the world. They are a successful, established
medical products company with strong networks to Physicians, Healthcare Providers, and the Government. We are very much looking forward to a rewarding collaboration with Biomedics.”
Abraham Renner, President and CEO of Biomedics commented, “We are very excited with this new venture, being at the frontline of medical technology requires constant innovation and creativity.
BIOJECT represents for us this trend and are confident that these devices will revolutionize the way we see medicine today. Mexico, with over 100 million people will soon benefit of this new technology and
position itself as a vanguard in health treatments.”
Yes. I believe this is underway.
They are in a position now, financially & organizationally, to become current with filings and benefit from the upside.
GLTA & JMO
But, really, they need to make the attempt to get current. Yes, it will cost them money, but the raise in share price would more than make up for it if they use stock for expenses. JMO.
They are delinquent but have made reasonable attempts to file unaudited numbers due to their lack of funds.
If you look at the recent move in management you may see that Tony has experience with SEC filings and I believe that is one reason they made the move; to get current with filings and such.
Its even possible that the SEC sent them a notice and was a catalyst for this compliance issue.
Becoming current again would be a shot in the arm (no pun intended) for this company/stock.
GLTA & JMO
BJCT is severely delinquent in filing their Financials and corporate filing obligations to the SEC. On Feb. 20, 2015 the SEC suspended 7 stocks from the Delinquent SEC Filers list, and it is likely that more delinquent Filers will be suspended.
Since Jan 1st, 2010 the SEC has suspended over 1290 stocks for Financials delinquencies. All of those Suspended stocks had their stock registrations revoked.
Shareholders should contact the company and pressure the Mgmt to file their delinquent Financials because ALL shareholders would be wiped out IF the SEC suspends the stock.
BJCT is on the list of delinquent filers:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110680509
Bioject Medical Technologies Inc. (OTCMKTS:BJCT) Makes Change In The Core Management Team
BY LYLE MILLIGAN • FEBRUARY 13, 2015
Science and improved information technology have brought many changes; one of them is needle-free injection therapy system. Amongst a few companies that develop this system, Bioject Medical Technologies Inc. (OTCMKTS:BJCT) shares a prominent place. As per the reports, BJCT has announced a major change in its management team.
Insights on the matter:
The biggest change in the management has been introduced at the top. Bioject Medical Technologies Inc. (OTCMKTS:BJCT) has appointed Mr. Tony Chow as the new CEO and President. Previously, he worked as the Chief Financial Officer of the company. Before his journey with BJCT began, Mr. Chow was the CFO of American Laser Healthcare Corporation, a well-known development stage medical device organization, with SEC reporting. His experience goes past 30 years, with expertise in financial management consulting and financial operations. He has rendered services in various fields such as financial/JSOX/IT compliance, SEC reporting, business development, software product development/implementations, and client relationship management.
The first senior management role came his way in 1989 when he was appointed as the Controller of InterTherapy, Inc., a promising start-up company. It was famous for manufacturing and marketing of intravascular catheter and caterer ultrasound imaging system. After a successful tenure at InterTherapy Inc., he joined Craig Consumer Electronics, Inc. in 1994 as Chief Financial Officer and Corporate Controller, and worked there until 1997. He served as Director of Asia sales at Digital Video Systems, Inc for the next two years before moving to his next assignment.
After being promoted, Mr. Chow stated that his main focus would be to expand the business of Bioject Medical Technologies Inc. (OTCMKTS:BJCT) in Asia and other international locations. He also mentioned Mark Logomasini, Director of Business Development, saying that he would seek his cooperation in expanding BJCT on domestic and international locations. According to him, the year 2015 is going to be very critical for him in terms of fulfilling stakeholders’ expectations.
http://traders350.com/bioject-medical-technologies-inc-otcmktsbjct-makes-change-in-the-core-management-team/721169/
Looks like the stabilization and growth phase is ramping up.
Management Change
Tigard, OR – February 12, 2015 – Bioject Medical Technologies Inc. (OTC Pink: BJCT), a leading developer and manufacturer of needle-free injection therapy systems, announced that Mr. Tony Chow has been appointed President and CEO of the company. Mr. Tony Chow was previously Bioject’s CFO. His back ground includes being the Chief Financial Officer at American Laser Healthcare Corporation, a development stage medical device company with SEC reporting. Mr. Tony Chow brings professional services experience with over 30 years in financial management consulting, financial operations including SEC reporting, financial/IT/JSOX compliance, business development, client relationship management, and software product development/implementations. From 1997 to 1999, Mr. Tony Chow was the Director of Asia Sales and Marketing at Digital Video Systems, Inc. From 1994 to 1997, Mr. Tony Chow was the Chief Financial Officer and Corporate Controller at Craig Consumer Electronics, Inc. From 1989 to 1993, Mr. Tony Chow was the Controller of InterTherapy, Inc., a start-up company in the manufacturing and marketing on intravascular caterer ultrasound imaging system and catheter.
Mr. Tony Chow stated, “Since I joined Bioject, I have seen a great opportunity for Bioject to expand in the international markets, especially in Asia. I believe Bioject is heading in a direction of growth. I will focus on the operations of the business and work with Mark Logomasini, Director of Business Development, in the expansion our domestic and international markets.”
Mr. Mark Logomasini, the prior President and CEO, will assume the new role and title of Director of Business Development for Bioject, “It's been my pleasure to serve as Bioject's President the past few years. We've invested in new markets and created a path for growth going forward. The focus now is to realize a return on that investment that benefits all of our stakeholders. With much of our attention overseas and the need to be especially rigorous in the evaluation of new opportunities, it's appropriate that Mr. Tony Chow take the helm at this time.”
Bioject Medical Technologies Inc., based in Tigard, Oregon, USA, is a developer and manufacturer of needle-free injection therapy systems (NFITS). NFITS works by forcing medication at high speed through a tiny orifice held against the skin. This creates a fine stream of high-pressure fluid penetrating the skin and depositing medication in the tissue beneath. Bioject is focused on developing mutually beneficial agreements with leading pharmaceutical, biotechnology, and veterinary companies, as well as research, global health and government organizations.
Bioject (OTC Pink: BJCT) trades on the OTC Pink tier of the OTC market. Investors can find Real-Time quotes and market information for the Company on www.otcmarkets.com.
Biojector 2000 in Hollywood. :)
https://www.facebook.com/video.php?v=779926232030052
And footage of the Zetajet.
https://www.facebook.com/video.php?v=727115280644481&set=vb.594115370611140&type=2&theater
Looking good. I do think BJCT has bottomed. Missed the late action. Was doing some bottom fishing today picking up 2500 sh of National Bank of Greece (NBG) @ $1.10
Not a bad day.
ASK moving up nicely.
Real volume would send this one soaring.
Looking forward to the Q.
GLTA & JMO
With baited breath. :)
GLTA
I will be following those earnings closely. If they are as I expect, I will finally jump in.
This co has promising technology.
Followers
|
17
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
821
|
Created
|
10/10/08
|
Type
|
Free
|
Moderators |
Bioject Medical Technologies Inc.
Bioject Medical Technologies Inc. (OTCBB: BJCT) is an emerging drug delivery company developing the world's leading technology for needle-free injection of liquid medications.
Bioject's technology works by forcing liquid medication at high speed through a tiny orifice held against the skin. This creates an ultra-fine stream of fluid that penetrates the skin, delivering medication in a fraction of a second. Bioject's systems are designed to deliver injected medications comfortably, accurately, and quickly - without the use of a needle. Bioject was founded in 1985 to develop needle-free injection systems to improve the comfort and safety of routine injections. Since then, Bioject has developed a broad technology platform for delivering many different types of medications and vaccines to the subcutaneous and intramuscular depths. The company is currently developing systems and is in clinical trials for intradermal injections.
Bioject has developed a portfolio of injection systems based on its core technology. These include durable devices designed for heavy use in a professional healthcare environment, and small, lightweight injectors designed for home use. With partners, Bioject is also developing an inexpensive, pre-filled, disposable injection systems. Bioject's strategy is to form strategic partnerships with leading pharmaceutical, biotechnology, and animal health companies. The company seeks to develop mutually beneficial agreements with these partners to develop customized injection systems to enhance the delivery of the partner's injected medication or vaccine. Bioject has alliances with leading pharmaceutical, biotechnology, and animal health companies.
Bioject Medical Technologies Inc.
20245 SW 95th Avenue
Tualatin, OR 97062
Phone: 503-692-8001
Fax: 503-692-6698
E-mail: investorrelations@bioject.com
Web: www.bioject.com
Bioject Medical Technologies Inc.is a fully reporting OTCBB stock: www.otcmarkets.com/pink/quote/quote.jsp
The company has recently confirmed that the share structure from the latest 10Q (3rd Quarter 2009) is still accurate: www.otcmarkets.com/edgar/GetFilingPdf
A/S: 100,000,000
O/S: 17,679,111 (confirmed by T/A on 4th March 2010)
Float: 13,800,000
The company has stated that at the current time they do not have any plans to dilute, as they recently closed a financing agreement with their largest shareholder. In the event they do need to dilute they would do it as a private placement which is usually done in the form of restricted shares that can not convert to common for 6 months, so we do not need to worry about dilution.
Transfer Agent
American Stock Transfer & Trust Company, LLC
59 Maiden Lane
Plaza Level
New York, NY 1003
Tel: (800) 937-5449 or (718) 921-8124
Web: www.amstock.com
Estimated Market Cap: $3,345,872 as of Mar 2, 2010
The Form 8K filed with the SEC for the company's financial year ending December 31st 2009 can be viewed here: http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=7133612
.
April 7th 2010: Bioject announces that it has met the final milestone under its Development Agreement with Merial Limited ("Merial") by delivering devices with auto-disable nozzles to Merial for its next generation spring-powered companion animal vaccination device. Bioject's President and Chief Executive Officer, Ralph Makar said "Merial has been an excellent partner and we appreciate the confidence Merial has in our needle-free technology. We are pleased to have completed this final milestone and look forward to using our new platform technology in its first commercial application". Full press release www.businesswire.com/portal/site/home/permalink/
March 17th 2010: Bioject published 4th Quarter and End of Year 2009 financials showing that the operating loss and net loss allocatable to common shareholders has decreased by 65% over the previous financial year. Bioject's President and Chief Executive Officer, Ralph Makar said "Recent positive events, such as the announcement of our strategic alliance with MPI Research, the elimination of our existing debt and the additional cash infusion, are encouraging as we strive for a better future and to increase shareholder value". Full press release http://www.marketwatch.com/story/bioject-reports-december-31-2009-results-2010-03-17?reflink=MW_news_stmp
February 22nd 2010: Bioject announced in a PR approval from the Swedish Medical Products Agency to conduct a phase I clinical trial evaluating an HIV/DNA vaccine in collaboration with the Karolinska Institutet (KI) and the Swedish Institute for Infectious Disease Control (SMI) to be delivered to healthy volunteers by ZetaJet® Full press release www.businesswire.com/portal/site/home/permalink/
February 16th 2010: Bioject announced in a PR full USDA license approval for Oncept canine melanoma vaccine, to be administered via a Canine Transdermal Device, which delivers the vaccine without the use of a needle. The device was developed in conjunction with Bioject, Inc. Full press release www.prnewswire.com/news-releases/merial-receives-full-license-approval-for-oncepttm-canine-melanoma-vaccine-84464667.html
January 5th 2010: Bioject announced that it has established a strategic alliance with MPI Research, a leading pre-clinical research organization with experience in the development of injectable therapeutics, which allows Bioject to gain access to a range of capabilities and resources needed for the company to explore drug+device opportunities, including access to pharmacologic, analytical, safety and other preclinical testing resources available at MPI Research. Full press release www.businesswire.com/portal/site/home/permalink/
December 21st 2009: Bioject announced it completed a Series G Preferred Stock financing with each of Life Sciences Opportunities Fund II, L.P., Life Sciences Opportunities Fund (Institutional) II, L.P. (collectively, the “LOF”), and Edward Flynn for the purchase of an aggregate of 92,448 shares of its Series G Convertible Preferred Stock at a price of $13.00 per share. Gross proceeds from the sale were $1,201,834, payable by payment of $500,000 in cash and the cancellation of the $600,000 outstanding principal amount of and $101,834 accrued interest. Full press release www.businesswire.com/portal/site/home/permalink/
April 6th 2009: Bioject announced that the U.S. Food and Drug Administration (FDA) has granted market clearance for the Zetajet™ Needle-Free Injection Therapy System. Bioject’s new ZetajetTM system is the latest advance in needle-free delivery systems, offering a significant array of unique product features and patient benefits that can provide highly competitive differentiation to a wide variety of injectables market segments. Full press release www.businesswire.com/portal/site/google/
************************************************************************************************************************************************************************************
Results from a sequential phase I and II, controlled, double-blinded study to determine whether immune responses suggesting protection against influenza can safely be induced in young children. The study commenced in October 2006 and was completed in November 2009, with study completion date set for May 2010. Good results from this study could be amazing for BJCT investors.
Clinical trials information www.clinicaltrials.gov/ct2/show/NCT00386542
Bioject's needle-free injection technology works by forcing liquid medication at high speed through a tiny orifice that is held against the skin. The diameter of the orifice is smaller than the diameter of a human hair. This creates an ultra-fine stream of high-pressure fluid that penetrates the skin without using a needle.
Bioject's technology is unique because it delivers injections to a number of injection depths and supports a wide range of injection volumes. For instance, the Biojector 2000 can deliver intramuscular or subcutaneous injections up to 1 mL in volume. In addition, Bioject is developing a syringe for the Biojector 2000 that delivers intradermal injections that is currently in clinical trials.
Intradermal* injections are very shallow injections that deposit the medication between the layers of the skin. Many new DNA-based vaccines are delivered to the intradermal layer.
Subcutaneous injections are delivered to the adipose (fat) layer just below the skin. Many therapeutic proteins are delivered to the subcutaneous depth, such as human growth hormone.
Intramuscular injections are the deepest injection type, delivering the medication into the muscle tissue. Most vaccines are currently delivered to the intramuscular depth.
The Bioject research and development team has developed a new spring-powered injector known as the ZetajetTM, which is based on the design of the Biojector® 2000 (B2000) for performance but uses a spring for its power source. The pressure profile of the Zetajet has been documented by in vitro testing to be virtually the same as that of the B2000, which has given millions of injections. The B2000 is a needle-free jet injection device that provides up-to-date jet injection technology and eliminates or reduces complications associated with others previous devices (eg, cross-contamination from patient to patient, lacerations at the injection site, difficult device cleaning, cumbersome tanks, etc).1-12 The intended use of this device is to provide a low-cost, needle-free injection system that delivers SC, IM, or ID injections via a simple change of the syringe. There is no need to adjust the device or technique for different injection types. This new needle-free system offers an additional feature - an auto-disable syringe that prevents re-use of the syringe. The syringe may be used to perform reconstitution with manual movement of the syringe plunger; however, once the injection is given, the syringe is disabled with the plunger tip remaining in the syringe to prevent any possible re-use.
A study comparing the use of Zetajet was conducted at a clinical centre in 2009. After meeting all eligibility criteria, a total of 60 healthy subjects were enrolled in this study and were given three injections. After each injection, a subjective evaluation was made related to the injection site, and questions were asked regarding the patients’ perceptions of the injection. Immediately after each injection, the injection sites were evaluated by a trained healthcare professional and within 5 minutes after the injections, the degree of pain with each injection was elicited from the subjects. The injection sites were also evaluated immediately following for local reactions (bruising, redness, and wheal formation). The follow-up was completed 24 hours after the initial injection and consisted of injection site evaluations.
The study reconfirmed the capability of a spring-powered device to successfully provide three types of injection (SC, ID, IM) that was originally proven using the Vitavax, a precursor device that led to the development of the Zetajet. The device was well received by the clinical investigators and clinicians who used the device during the study. Comments received throughout the trial regarding the ease of winding, loading, and administering the injection by the clinical investigators was very positive. On the assessments by injection type, all three injection methods with Zetajet received very positive ratings with more than 96% overall receiving Extremely Favorable and Favorable ratings.
In conclusion, the results of this clinical trial indicate that the Zetajet needle-free injection system is preferred compared to a traditional needle and syringe system. It also demonstrated the subjective injection effectiveness of the Zetajet jet injection system for SC, ID, and IM injections.With these unique advances in delivery technology, the Zetajet is anticipated to provide the optimal injection therapy system for both developed and developing countries to provide a safer and more effective method for delivering their parenteral injectables.
The full study report can be downloaded here http://www.bioject.com/pdf/Zetajet%20DDT%20Article%20February%202009%20Low%20Res.pdf
The Biojector® 2000 is a durable, professional-grade injection system designed for healthcare providers. The Biojector® 2000 is the only needle-free system in the world cleared by the FDA to deliver intramuscular injections. The system can also deliver subcutaneous injections, and is being used for intradermal injections in clinical trials.
Cool.clickTM is a needle-free injection system designed for delivery of Saizen® recombinant human growth hormone. Serono, the manufacturer of Saizen, is the first company to offer a needle-free delivery system for human growth hormone injection that is cleared by the FDA.
SeroJetTM needle-free injection system designed for delivery of Serostim, Serono’s high-dose recombinant human growth hormone formulation that is the leading treatment for AIDS wasting. Serostim has been the most extensively tested in AIDS wasting and the only biotechnology-derived drug approved for AIDS wasting by the FDA in the USA, which has granted Serostim orphan drug status, and marketing exclusivity, in the United States until August 2003.
The Vial Adapter Drug Reconstitution Adapter Kit includes a blunt plastic device that replaces a fill needle for accessing medication vials, making syringe filling completely needle-free. The Vial adapter is designed to fit all standard syringes and all standard 13mm vials. The system is a convenient method for the withdrawal of medication and the transfer of diluents for reconstitution without the use of a needle.
The Bioject® needle-free drug reconstitution vial adapter is a non-sharp plastic device that replaces a fill needle for accessing medication vials making syringe filling completely needle-free. The vial adapter is designed to fit all standard syringes and fits on a drug vial with a 13 mm neck. The system is a convenient method for the withdrawal of medication and the transfer of diluents for reconstitution without the use of a needle.
Please mark this board as a favorite and let's get more eyeballs here!
Suggestions for improvements and updates to the iBox are welcomed. PM Rick-UK with your ideas!
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |